ArticleWorld journal of urology2025
PSMA-PET/CT-based salvage elective nodal radiotherapy for lymph node recurrence following radical prostatectomy.
Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Early Identification and Management of Biochemical Recurrence Following Radical Prostatectomy.Annals of surgical oncology · 2026Review
- PSMA PET in Lymph Node Staging of Prostate Cancer: From Diagnostic Accuracy to Clinical Decision-Making.Cancers · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeFor patients with oligometastatic nodal recurrence after radical prostatectomy (RP), salvage radiotherapy is a valuable curative second-line treatment option. However, few clinical data on the impact of PSMA-PET/CT-based salvage elective nodal radiotherapy (sENRT) is available. In order to contribute further clinical data on the outcome of patients treated with sENRT following RP, we analysed the rates of biochemical recurrence-free survival (BRFS) and distant metastasis-free survival (DMFS) as well as potential predictive markers for optimised patient selection.
methodsA retrospective analysis of 76 patients treated with sENRT for nodal recurrence after RP was performed. Primary endpoints were BRFS and DMFS. Cox proportional hazards model was used to analyse potential predictive factors.
resultsMedian follow-up was 32.6 months. PSMA-PET/CT revealed 1, 2, or ≥ 3 positive lymph nodes in 63.2%, 30.2% and 6.6% of patients, respectively. 96% of the patients had pelvic-only lymph nodes involvement. One-, two- and three-year BRFS were 98.6%, 84.2%, and 71.9%, respectively. Notably, nodal status at the time of RP and biochemical-recurrence prior to sENRT, were associated with reduced BRFS. One-, two-, and three-year DMFS were 98.7%, 94.1%, and 94.1%, respectively, with paraaortic lymph nodes being the only factor indicating reduced DMFS. Concomitant androgen-deprivation therapy was applied in 85.5% of the patients.
conclusionWe present one of the largest studies on PSMA-PET-based sENRT for nodal recurrence after RP with promising results, highlighting the important role of sENRT. Regarding patient selection, initial lymph node status and prior radiation of the prostate were predictive of reduced BRFS, while involvement of paraaortic lymph nodes was identified as marker for reduced DMFS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.